

1992

Phosphatidylserine Found in Intestinal Mucus Serves as a Sole Source of Carbon and Nitrogen for Salmonellae and *Escherichia coli*

Howard C. Krivan

David P. Franklin
University of Rhode Island

See next page for additional authors

Follow this and additional works at: https://digitalcommons.uri.edu/cels_past_depts_facpubs

Terms of Use

All rights reserved under copyright.

Citation/Publisher Attribution

Krivan, H. C., Franklin, D. P., Wang, W., Laux, D. C., & Cohen, P. S. (1992). Phosphatidylserine Found in Intestinal Mucus Serves as a Sole Source of Carbon and Nitrogen for Salmonellae and *Escherichia coli*. *Infect. Immun.*, 60(9), 3943-3946. Retrieved from <https://iai.asm.org/content/60/9/3943>.

Available at: <https://iai.asm.org/content/60/9/3943>

This Article is brought to you for free and open access by the College of the Environment and Life Sciences at DigitalCommons@URI. It has been accepted for inclusion in Past Departments Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.

Authors

Howard C. Krivan, David P. Franklin, Wietong Wang, David C. Laux, and Paul S. Cohen

Phosphatidylserine Found in Intestinal Mucus Serves as a Sole Source of Carbon and Nitrogen for *Salmonellae* and *Escherichia coli*

HOWARD C. KRIVAN,^{1*} DAVID P. FRANKLIN,² WIETONG WANG,¹
DAVID C. LAUX,² AND PAUL S. COHEN²

MicroCarb Inc., Suite 100, 300 Professional Drive, Gaithersburg, Maryland 20879,¹ and Department of Microbiology, University of Rhode Island, Kingston, Rhode Island 02881²

Received 1 April 1992/Accepted 24 June 1992

Salmonella choleraesuis (a pig pathogen), *Salmonella typhimurium* (a virulent strain in mice), and three strains of *Escherichia coli* (including a human enterohemorrhagic strain, a human urinary tract isolate, and a human fecal isolate) grew as well in vitro utilizing the lipids derived from mouse cecal mucus as the sole source of carbon and nitrogen as they did in mouse crude cecal mucus. Further analysis of the total lipid extracts of mucus dialysates showed that the acidic lipid fraction supported growth nearly as well as the total lipid fraction. Interestingly, among the many purified acidic lipids from mucus which were tested and analyzed, including several phospholipids, only phosphatidylserine was found to support the growth of all of these enteric bacteria, including *Salmonella milwaukee*, a human pathogen. The possible role of growth on pure phosphatidylserine in the pathogenesis of salmonellae is discussed.

The mucus gel of the gastrointestinal tracts of humans and animals has been suggested to function as an important barrier to bacterial infection and invasion by entrapping enteric pathogens and inhibiting their attachment to the underlying mucosal cell surface (2). The mucus gel has also been suggested to serve as an important substrate for commensal mucin-degrading bacteria (11, 18) and as colonization sites for other enteric bacteria (6, 7, 13, 16). Mucus occurs as a viscous, sticky, water-insoluble gel which is composed of a high-molecular-weight glycoprotein (mucin) and smaller proteins and glycoproteins, although it is now known that many lipids are also associated noncovalently with the gel layer (17, 21). It has recently been shown that for *Escherichia coli* and *Salmonella typhimurium* to colonize the colons of streptomycin-treated mice, they must be able to grow in the mucus layer (12, 20). The data that we present here indicate that several serovars of *Salmonella* and *E. coli* are able to utilize lipids existing in the mucus layer for growth, of which phosphatidylserine was found to serve as the sole source of both carbon and nitrogen for growth for all of these enteric bacteria.

Dialysates of male CD-1 mouse cecal mucus, which support growth of *E. coli* and *S. typhimurium* as well as crude cecal mucus does in vitro (8), were used as the source of cecal mucus lipids. Lipids were extracted from mucus dialysates in chloroform-methanol-water (4:8:3) (19) or in chloroform-methanol (2:1) (17) and separated into neutral and acidic fractions by high-performance liquid chromatography (HPLC) on silica Iatrobeads (1) and by anion-exchange chromatography on DEAE-cellulose, respectively (15). Each lipid fraction was dried under nitrogen and dispersed by sonication into HEPES (*N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid)-Hanks buffer, pH 7.4, at 1 mg/ml, and the samples were inoculated with about 2×10^4 CFU of bacteria per ml. As shown in Table 1, *S. typhimurium* SL7312, a virulent strain, and *E. coli* F-18, a normal human

fecal strain (4), grew essentially as well utilizing cecal mucus total lipids as the sole source of carbon and nitrogen as in the cecal mucus dialysate itself for the first 6 h of incubation at 37°C. Moreover, in the presence of total cecal mucus lipids, levels (CFU per milliliter) of about 20% of that reached in cecal mucus dialysates at 24 h were observed (Table 1). The cecal mucus acidic lipids were also effective in promoting growth, whereas the neutral lipid fraction was relatively ineffective (Table 1). Interestingly, the pattern of growth of *Salmonella choleraesuis* 735B, a pig pathogen, was identical to that of *S. typhimurium* in cecal mucus total lipids and acidic lipids (data not shown), and *E. coli* 933 EDL (O157:H7), a human enterohemorrhagic strain, and *E. coli* A55 (O6, Pap⁺ Hly⁺), a pathogen causing human urinary tract infections, grew in the total and acidic fractions essentially identically to *E. coli* F-18 (data not shown).

Gangliosides, sulfatides, and phospholipids make up the majority of acidic lipids of mammalian cells, whereas the majority of neutral lipids are glycosphingolipids (10). Therefore, several phospholipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, and sphingomyelin [Avanti Polar Lipids, Inc., Alabaster, Ala.]), purified mixtures of standard monosialogangliosides (GM₁, GM₂, and GM₃ [BioCarb Chemicals, Lund, Sweden]), disialogangliosides (GD_{1a}, GD_{1b}, GD₂, and GD₃ [BioCarb Chemicals]), and a standard mixture of neutral glycosphingolipids which contained galactosylceramide, lactosylceramide, globotriaosylceramide, globoside, and Forssman glycolipid (BioCarb Chemicals) were tested for their ability to support the growth of *E. coli* and salmonellae. Neither the *E. coli* nor the *Salmonella* strains grew to any great extent on the mixtures of known standard gangliosides or neutral glycosphingolipids (Table 2). Of the purified phospholipids used as the sole source of carbon and nitrogen, only phosphatidylserine supported growth of *S. typhimurium* SL7312 and *E. coli* F-18 to any great extent (Table 3). The other phospholipids were unable to support the growth of these bacteria. Similarly, phosphatidic acid, a combination of phosphatidic acid and L-serine, L-serine

* Corresponding author.

TABLE 1. Growth of *S. typhimurium* SL7312 and *E. coli* F-18 on cecal mucus lipids as the sole source of carbon and nitrogen

Substrate	CFU relative to input CFU ^a at:			
	6 h		24 h	
	F-18	SL7312	F-18	SL7312
Dialysate	264	1,506	6,436	12,875
Total lipids ^b	620	916	1,551	2,125
Acidic lipids	158	416	437	625
Neutral lipids	0.14	1.83	0.02	4.44
HH ^c	0.55	0.85	2.53	6.55

^a Input CFU per milliliter: *E. coli* F-18, 8.1×10^4 ; *S. typhimurium* SL7312, 6.6×10^4 .

^b Lipids were dispersed in HEPES-Hanks buffer, pH 7.4, at a concentration of 1 mg/ml.

^c HEPES-Hanks buffer, pH 7.4.

alone, and *O*-phospho-L-serine (Sigma Chemical Co., St. Louis, Mo.) did not support growth, although L-serine and *O*-phospho-L-serine did allow low levels of growth by 24 h (Table 3). Together, the data suggest that phosphatidylserine itself is transported and then metabolized. The human enterohemorrhagic *E. coli* and urinary tract infection-causing strains also utilized phosphatidylserine for growth to the same extent as *E. coli* F-18 (data not shown), and *S. choleraesuis* 735B utilized phosphatidylserine to the same extent as *S. typhimurium* SL7312 (Table 4). Similarly, *S. milwaukee*, a human pathogen, utilized phosphatidylserine for growth as efficiently as the other *Salmonella* strains (data not shown). Phosphatidylserine obtained from Sigma Chemical Co. (bovine brain, 98% pure) or from Avanti Polar Lipids (bovine brain, >99% pure) supported growth of the *Salmonella* and *E. coli* strains in a similar fashion (data not shown).

To determine the amount of phosphatidylserine present in mouse cecal mucus, the acidic lipid fraction was hydrolyzed with 6 N HCl for 18 h at 120°C, and released serine was measured by the PICO-TAG method with phenyl isothiocyanate (5). Derivatized serine was separated and quantified by reverse-phase HPLC with a Supelcosil LC-18 column (3). As shown in Fig. 1, the HPLC profile obtained from the acidic lipid fraction (Fig. 1b) included a peak with a retention value identical to that of the authentic phosphatidylserine standard (Fig. 1a). Comparative analysis of the integrated peak areas indicated that 33.5 μg of phosphatidylserine per mg of total

TABLE 2. Growth of *E. coli* F-18 and *S. typhimurium* SL7312 on a mixture of standard acidic glycosphingolipids (gangliosides) and neutral glycosphingolipids

Substrate	CFU relative to input CFU ^a at:			
	6 h		24 h	
	F-18	SL7312	F-18	SL7312
Monosialogangliosides ^b	0.69	0.89	0.10	3.25
Disialogangliosides	0.75	1.52	0.02	5.45
Neutral glycosphingolipids	0.92	1.39	<0.02	5.16
HH ^c	0.85	0.81	0.21	1.69

^a Input CFU per milliliter: *E. coli* F-18, 5.2×10^4 ; *S. typhimurium* SL7312, 6.4×10^4 , where data are presented as the ratios of CFU at 6 and 24 h to the input CFU.

^b Mixtures of purified standards were dispersed in HEPES-Hanks buffer, pH 7.4, at a concentration of 1 mg/ml.

^c HEPES-Hanks buffer, pH 7.4.

TABLE 3. Growth of *S. typhimurium* SL7312 and *E. coli* F-18 on selected purified phospholipids

Substrate ^a	CFU relative to input CFU ^b at:			
	6 h		24 h	
	F-18	SL7312	F-18	SL7312
Phosphatidylserine	6.78	21.91	203	1,319
Phosphatidylcholine	1.70	1.10	6.65	3.47
Phosphatidylethanolamine	0.74	0.49	0.52	0.70
Phosphatidylinositol	1.60	0.66	0.91	0.51
Sphingomyelin	0.65	0.36	0.30	0.12
Phosphatidic acid + L-serine	1.26	0.55	0.52	0.19
Choline chloride	3.42	2.44	2.63	4.71
L-Serine	1.62	1.71	21.53	36.06
<i>O</i> -Phospho-L-serine	2.41	3.62	31.13	36.52
HH ^c	1.39	0.78	0.74	0.45

^a Unless otherwise noted, all substrates were suspended in HEPES-Hanks buffer, pH 7.4, at 1 mg/ml.

^b Input CFU per milliliter: *E. coli* F-18, 2.3×10^4 ; *S. typhimurium* SL7312, 4.7×10^4 .

^c HEPES-Hanks buffer, pH 7.4.

lipid extracted from mouse cecal mucus was present. In addition, cecal mucus dialysate, total lipids, and phosphatidylserine were treated with phospholipase A₂ (Sigma Chemical Co.) to cleave the fatty acid from the 2 position of the phospholipids and with phospholipase D (Sigma Chemical Co.) to hydrolyze the two fatty acids from each phospholipid. The enzyme-treated samples were dialyzed against water, and each enzyme-free dialysate was lyophilized, resuspended in water to its original volume, and inoculated at about 5×10^4 CFU/ml with either *S. typhimurium* SL7312 or *E. coli* F-18. As shown in Table 5, the enzyme-treated samples did not support growth nearly as well as the untreated samples. Therefore, these data further support the view that phospholipids, and more specifically, phosphatidylserine, are primarily responsible for *Salmonella* and *E. coli* growth in mouse cecal mucus dialysates.

E. coli and salmonellae are known to utilize long-chain fatty acids as the sole source of carbon after a long lag period (14) and to use L-serine as the sole source of carbon and nitrogen (9). To our knowledge, however, nothing regarding the ability of salmonellae and *E. coli* to utilize lipids as the sole source of carbon and nitrogen is known. In the present study, we have focused on those lipids present in cecal

TABLE 4. Growth of *S. typhimurium* SL7312 and *S. choleraesuis* 735B on selected purified phospholipids

Substrate ^a	CFU relative to input CFU ^b at:			
	6 h		24 h	
	SL7312	735B	SL7312	735B
Phosphatidylserine	29.18	28.10	222	533
Phosphatidylcholine	2.06	5.48	3.10	5.28
Phosphatidylethanolamine	0.43	0.81	1.42	1.95
Phosphatidylinositol	0.43	1.24	0.80	3.38
Phosphatidic acid	0.20	1.38	1.04	2.33
HH ^c	0.37	1.48	0.88	2.48

^a Phospholipids were dispersed in HEPES-Hanks buffer, pH 7.4, at a concentration of 1 mg/ml.

^b Input CFU per milliliter: *S. typhimurium* SL7312, 4.9×10^4 ; *S. choleraesuis* 735B, 2.1×10^4 .

^c HEPES-Hanks buffer, pH 7.4.




FIG. 1. Results of HPLC of serine hydrolytically released from phosphatidylserine. Standard phosphatidylserine (1 μ g) (a) and the acidic lipid fraction of mouse cecal mucus (20 μ g) (b) were hydrolyzed and derivatized with phenyl isothiocyanate and were injected onto a Supelcosil LC-18 column (250 by 4.6 mm). The column was eluted with a linear gradient of ammonium acetate-trimethylamine as described previously (3) by using a UV detector operated at 254 nm.

mucus preparations and have demonstrated that salmonellae and *E. coli* are capable of utilizing cecal mucus total lipids, the corresponding acidic lipid fraction, and phosphatidylserine as the sole sources of carbon and nitrogen and that they do so without an extended lag period. Moreover, in the case of *S. typhimurium*, it will be of interest to determine whether the ability to utilize phosphatidylserine is required for pathogenesis in the mouse intestine. For example, it is possible that the ability to metabolize the phosphatidylserine present in intestinal epithelial cell membranes is required for successful invasion by salmonellae of intestinal epithelial cells. Interestingly, these findings may also explain why salmonellae survive and grow in chicken eggs, which are rich in phospholipids, including phosphatidylserine.

TABLE 5. Effect of phospholipase treatment on growth of *S. typhimurium* SL7312 and *E. coli* F-18

Strain	Phospholipase ^a	CFU relative to input CFU ^b in the indicated substrate		
		Dialysate	Total lipids	Phosphatidylserine
SL7312	None	388	162	43.3
	A ₂	2.52	1.02	1.81
	D	2.28	2.74	4.05
F-18	None	479	221	87.2
	A ₂	39.7	10.7	4.14
	D	45.5	5.51	5.86

^a Samples were treated with either none or 1 U of each phospholipase for 6 h at 37°C. Untreated samples were incubated without enzymes for 6 h at 37°C and then were dialyzed, lyophilized, resuspended, and inoculated identically to the phospholipase-treated samples.

^b Input CFU per milliliter: *S. typhimurium* SL7312, 4.2×10^4 ; *E. coli* F-18, 2.9×10^4 . Incubation was at 37°C for 6 h.

This work was supported, in part, by Public Health Service grant AI1670 to P.S.C. and D.C.L. from the National Institute of Allergy and Infectious Diseases.

We gratefully acknowledge the excellent technical assistance of Mac Richardson and Xin Zhou.

ADDENDUM IN PROOF

Data obtained after acceptance of this paper show that *E. coli* and salmonellae can also utilize phosphatidylserine as the sole source of phosphate for growth.

REFERENCES

1. Ando, S., M. Isobe, and Y. Nagai. 1976. High performance preparative column chromatography of lipids using a new porous silica, Iatrobeads. I. Separation of molecular species of sphingoglycolipids. *Biochim. Biophys. Acta* 424:98-105.
2. Beachey, E. H. 1981. Bacterial adherence: adhesion-receptor interactions mediating the attachment of bacteria to mucosal surfaces. *J. Infect. Dis.* 143:325-345.
3. Bidlingmeyer, B. A., S. A. Cohen, and T. L. Tarvin. 1984. Rapid analysis of amino acids using pre-column derivatization. *J. Chromatogr.* 336:93-104.
4. Cohen, P. S., R. Rossoll, V. J. Cabelli, S.-L. Yang, and D. C. Laux. 1983. Relationship between the mouse colonizing ability of a human fecal *Escherichia coli* strain and its ability to bind a specific mouse colonic mucous gel protein. *Infect. Immun.* 40:62-69.
5. Cohen, S. A., B. A. Bidlingmeyer, and T. L. Tarvin. 1986. PTC derivatives in amino acid analysis. *Nature (London)* 320:769-770.
6. Conway, P. L., A. Welin, and P. S. Cohen. 1990. Presence of K88-specific receptors in porcine ileal mucus is age dependent. *Infect. Immun.* 58:3178-3182.
7. Drumm, B., A. M. Robertson, and P. M. Sherman. 1988. Inhibition of attachment of *Escherichia coli* RDEC-1 to intestinal microvillus membranes by rabbit ileal mucus and mucin in vitro. *Infect. Immun.* 56:2437-2442.
8. Franklin, D. P., D. C. Laux, T. J. Williams, M. C. Falk, and P. S. Cohen. 1990. Growth of *Salmonella typhimurium* SL5319 and *Escherichia coli* F-18 in mouse cecal mucus: role of peptides and iron. *FEMS Microbiol. Ecol.* 74:229-240.
9. Gutnick, D., J. M. Calvo, T. Klopotoski, and B. N. Ames. 1969. Compounds which serve as the sole source of carbon or nitrogen for *Salmonella typhimurium* LT-2. *J. Bacteriol.* 100:215-219.
10. Hakomori, S. 1983. Chemistry of glycosphingolipids, p. 1-165. In J. N. Kanfer and S. Hakomori (ed.), *Handbook of lipid research. Sphingolipid biochemistry*. Plenum Press, New York.
11. Hoskins, L. C., M. Agustines, W. B. McKee, E. T. Boulding, M. Kriaris, and G. Niedermeyer. 1985. Mucin degradation in human colon ecosystems. Isolation and properties of fecal strains that degrade ABH blood group antigens and oligosaccharides from mucin glycoproteins. *J. Clin. Invest.* 75:944-953.
12. McCormick, B. A., B. A. D. Stocker, D. C. Laux, and P. S. Cohen. 1988. Roles of motility, chemotaxis, and penetration through and growth in intestinal mucus in the ability of an avirulent strain of *Salmonella typhimurium* to colonize the large intestine of streptomycin-treated mice. *Infect. Immun.* 56:2209-2217.
13. Mouricout, M. A., and R. A. Julien. 1987. Pilus-mediated binding of bovine enterotoxigenic *Escherichia coli* to calf small intestinal mucins. *Infect. Immun.* 55:1216-1223.
14. Nunn, W. D. 1987. Two-carbon compounds and fatty acids as carbon sources, p. 285-301. In F. C. Neidhardt, J. L. Ingraham, K. B. Low, B. Magasanik, M. Schaechter, and H. E. Umbarger (ed.), *Escherichia coli and Salmonella typhimurium: cellular and molecular biology*. American Society for Microbiology, Washington, D.C.
15. Rouser, G., G. Kritchevsky, and A. Yamamoto. 1976. Lipid chromatographic analysis, p. 713-776. In G. Rouser (ed.), *Lipid*

- chromatographic analysis, vol. 3. Marcel Dekker, Inc., New York.
16. Sajjan, S. U., and J. F. Forstner. 1990. Characteristics of binding of *Escherichia coli* serotype O157:H7 strain CL-49 to purified intestinal mucin. *Infect. Immun.* **58**:860–867.
 17. Slomiany, A., Y. Shingo, B. L. Slomiany, and G. B. J. Glass. 1978. Lipid composition of the gastric mucous barrier in the rat. *J. Biol. Chem.* **253**:3785–3791.
 18. Stanley, R. A., S. P. Ram, R. K. Wilkinson, and A. M. Robertson. 1986. Degradation of pig gastric and colonic mucins by bacteria isolated from the pig colon. *Appl. Environ. Microbiol.* **51**:1104–1109.
 19. Svennerholm, L., and P. Fredman. 1980. A procedure for the quantitative isolation of brain gangliosides. *Biochim. Biophys. Acta* **617**:97–109.
 20. Wadolkowski, E. A., D. C. Laux, and P. S. Cohen. 1988. Colonization of the streptomycin-treated mouse large intestine by a human fecal *Escherichia coli* strain: role of growth in mucus. *Infect. Immun.* **56**:1030–1035.
 21. Witas, H., J. Sarosiek, M. Aono, V. L. N. Murty, A. Slomiany, and B. L. Slomiany. 1983. Lipids associated with rat small-intestinal mucus glycoprotein. *Carbohydr. Res.* **120**:67–76.